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Abstract 
Background 
There is growing interest in the use of routinely collected electronic health records to 
enhance service delivery and facilitate clinical research. It should be possible to detect and 
measure patterns of care and use the data to monitor improvements but there are 
methodological and data quality challenges. Driven by the desire to model the impact of a 
patient self-test blood count monitoring service in patients on chemotherapy, we aimed to 
(i) establish reproducible methods of process-mining electronic health records, (ii) use the 
outputs derived to define and quantify patient pathways during chemotherapy, and (iii) to 
gather robust data which is structured to be able to inform a cost-effectiveness decision 
model of home monitoring of neutropenic status during chemotherapy. 
Methods 
Electronic Health Records at a UK oncology centre were included if they had (i) a diagnosis 
of metastatic breast cancer and received adjuvant epirubicin and cyclosphosphamide 
chemotherapy or (ii) colorectal cancer and received palliative oxaliplatin and infusional 5-
fluorouracil chemotherapy, and (iii) were first diagnosed with cancer between January 2004 
and February 2013. Software and a Markov model were developed, producing a schematic 
of patient pathways during chemotherapy.  
Results 
Significant variance from the assumed care pathway was evident from the data. Of the 535 
patients with breast cancer and 420 with colorectal cancer there were 474 and 329 pathway 
variants respectively. Only 27 (5%) and 26 (6%) completed the planned six cycles of 
chemotherapy without having unplanned hospital contact. Over the six cycles, 169 (31.6%) 
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patients with breast cancer and 190 (45.2%) patients with colorectal cancer were admitted 
to hospital.   
Conclusion 
The pathways of patients on chemotherapy are complex.  An iterative approach to addressing 
semantic and data quality issues enabled the effective use of routinely collected patient records to 
produce accurate models of the real-life experiences of chemotherapy patients and generate 
clinically useful information.  Very few patients experience the idealised patient pathway that is used 
to plan their care. A better understanding  of real-life clinical pathways through process mining  can 
contribute to care and data quality assurance, identifying unmet needs, facilitating quantification of 
innovation impact, communicating with stakeholders, and ultimately improving patient care and 
outcomes.   
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Introduction 
 
Over the last 30 years, Western medicine has become increasingly systematised (1, 2). 
Drivers bringing this about include a call for improvements in quality, the desire to 
standardise care, a need to disseminate best practice, demands for cost containment 
coupled with rising demand and not least, patient safety (3). An important tool in this regard 
has been clinical pathways that establish the expected standard of care and the processes 
and procedures that should be followed (4). These pathways are becoming more evidence 
based (5, 6), but such evidence is generally derived from carefully structured clinical trials 
rather than learning directly from routine clinical practice which can be very different. 
Moreover, the majority of such clinical pathways are linear, relate to single conditions, and 
do not reflect real-life variations in individual patient genotype, phenotype, co-morbidities, 
environment and response to treatment. There are, therefore, good reasons to question 
whether perceived patterns of existing care are accurate and meaningful when used to plan 
and evaluate patient management. 
 
With the trend towards integrated care and electronic health record (EHR) systems, a 
wealth of data on what actually happens to patients during their episodes of care are 
ƉŽƚĞŶƚŝĂůůǇĂǀĂŝůĂďůĞ ?/ŶŽŶĐŽůŽŐǇ ?ƚŚĞƌĞŝƐŝŶĐƌĞĂƐŝŶŐĂƚƚĞŶƚŝŽŶŽŶƚŚĞƵƐĞŽĨ “ďŝŐĚĂƚĂ ? (7), 
with much of the focus being on applications of next generation sequencing genomics (8). 
Process mining is ŽŶĞĞŵĞƌŐŝŶŐ  “ďŝŐĚĂƚĂ ?approach for discovering and analysing process 
models based on the very large event logs contained within information systems (9) and 
there is a growing body of literature on process mining in healthcare (10).  Our review of the 
process mining literature identified 37 peer reviewed papers using electronic health record 
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(EHR) data to map pathways in oncology (11). Challenges included the difficulty of capturing 
outpatient events (12), the use of data collected for non-clinical purposes, missing data and 
clinically inaccurate time-stamps (13). Our chemotherapy pathway mapping addressed 
these issues and is comprehensive and patient-centred, reporting most contacts the patient 
has with the hospital including in- and outpatient events, telephone contacts and pathology 
results. We use a novel iterative approach to addressing data quality through using clinical 
review to refine the model. We argue that mining true real-life clinical pathways of patients 
with cancer will facilitate the visualisation, quantification and improvement of such 
pathways.   
 
The United Kingdom (UK) is in a strong position to address the issue of acquiring and 
applying lessons learned to improve complex patient pathways and outcomes due to the 
comprehensive nature of the National Health Service (NHS) model which extends across 
primary and secondary care with equity of access for all. The challenges were identified by 
the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) in 2008, which 
reported that 42% of patients who died within thirty days of systemic anticancer therapy 
were admitted with a treatment related complication to a general medical ward, rather 
than to a ward with oncology-specific expertise (14).  This identified problems at a high level 
with limited amount of detail.  The NCEPOD and the National Chemotherapy Advisory Group 
highlighted the incompleteness of patient records, many of which were paper-based at the 
time, along with shortcomings of conventional real-life data collection (15). In the UK, EHRs 
are now commonly used in routine practice to collect comprehensive clinical data in all 
patients, at all points of care. We used a large and comprehensive EHR to study clinical 
pathways in patients with cancer receiving chemotherapy and their risk of developing 
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neutropenic infections in order to get a more detailed understanding of neutropenic 
complications during chemotherapy. 
  
We describe a methodology to extract detailed information on individual patient care 
pathways from Patient Pathway Manager (PPM), a mature, large and comprehensive EHR 
which has been in place for patients with cancer for over a decade in Leeds Teaching 
Hospitals NHS Trust (LTHT) (16, 17). We studied patients with two common malignancies, 
breast and colorectal cancer, receiving two frequently used chemotherapy regimens; 
adjuvant epirubicin and cyclophosphamide (EC90) and palliative oxaliplatin and modified de 
Gramont 5-fluorouracil (OxMdG). The key objectives of this study were (i) to establish 
reproducible methods of mining EHRs, (ii) to define accurate clinical pathways of patients 
with cancer on chemotherapy, and (iii) to gather robust data that is structured to inform a 
cost-effectiveness decision model of home monitoring of neutropenic status during 
chemotherapy.  
 
Materials & Methods 
Patient Pathway Manager (PPM) 
PPM is a mature EHR that is used to capture comprehensive clinical data on all patients 
undergoing treatment for cancer at the Leeds Cancer Centre within LTHT.  Initially 
developed in 2003 to support collection of the National Cancer Dataset, the system has 
been extended to collect comprehensive coded data to support the collection and reporting 
of the Cancer Outcomes Services Dataset (18). The system integrates electronic data held 
within multiple disparate systems within the Trust into a single EHR database including data 
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on patient admissions and out-patient events from the Patient Administration System (PAS), 
chemotherapy data from Chemocare (19), radiotherapy data from Mosaiq (20), blood, 
pathology and microbiology results from laboratory systems and data entered directly into 
PPM including surgery, cancer waiting times and multi-disciplinary team meetings (Figure 1). 
The system has recently been extended to collate data on all patients whose care has been 
delivered at LTHT since 2000 and contains the records of more than 2.39 million patients. It 
is therefore one of the largest hospital EHRs in the UK. The PPM system now underpins the 
move away from paper records at LTHT and also provides the platform for the Leeds Care 
Record, a common integrated digital care record used across the Leeds City Region for 
primary, secondary/tertiary care, social care, community care and mental health services. 
Within PPM, each event is recorded with a patient identification and metadata, including 
date time stamp, enabling a historical pathway to be extracted for every patient. 
Patient Selection Criteria 
Patient records were included if the patient had (i) a diagnosis of breast cancer (ICD-10 C50) 
and received epirubicin and cyclophosphamide (EC90) chemotherapy as adjuvant treatment 
or (ii) a diagnosis of colorectal cancer (ICD-10 C18-C20) and received oxaliplatin and 
infusional 5-fluorouracil chemotherapy (OxMdG) in the palliative setting. Breast and colo-
rectal cancer were selected as both are common cancers in which chemotherapy plays an 
important role. The breast cancer setting was adjuvant, whereas the patients with colo-
rectal cancer were being treated with palliative intent; we sought, therefore, to select 
populations with potentially different challenges. The chemotherapy regimens chosen 
represented those most commonly used in Leeds Cancer Centre in the specified time period 
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in each setting.  Patients first diagnosed with the cancer between 1st January 2004 and 1st 
February 2013 were included; 535 with breast cancer and 420 with colorectal cancer.  
 
Figure 1: Overview of data entered into PPM.  
MDT - multi-disciplinary team, Chemocare - chemotherapy electronic prescribing   system, 
PAS - patient administration system, Results server - LTHT software importing all patient 
investigation results from multiple disciplines, CWT - cancer waiting times, MOSAIC - 
radiation oncology software, ePRO - clinical information management system working with 
tŝŶƐĐƌŝďĞ ?Ɛ ĚŝŐŝƚĂů ĚŝĐƚĂƚŝŽŶ ƐǇƐƚĞŵ ? ƚĞůĞƉŚŽŶĞ ĐŽŶƚĂĐƚ  W hospital staff telephone patient, 
patient telephone inquiries  W patient rings hospital with a clinical inquiry.  
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Computing Resources  
An information technology data analyst developed the data extraction and transformation 
software and developed the pathway model as described in the next section (Data mining 
software & Markov model development). Data in PPM is stored in a Microsoft SQL database 
and records for the two patient groups were extracted using C# with embedded SQL queries 
to create a secure Microsoft SQL database containing all relevant events. The software 
followed the extract, transform and load (ETL) design pattern (21). Transformations to the 
data were coded to address completeness, quality, exclusion and aggregation issues and 
followed a change control process with clinical oversight. The data was used to generate 
Comma Separated Value (CSV) exports of aggregate figures and animated visualisations of a 
Markov model. The key elements of Markov models are described in Appendix A. The 
software was run on a secure LTHT machine with an Intel Core I7 processor with 16GB of 
memory.   
Data Mining Software & Markov Model Development 
Data modelling followed a disciplined agile development process with eight iterations in 
total (22). The first iteration started with a simplified model schematic of the patient 
pathway based on expert opinion (Figure 2); this was followed by the development of the 
initial data mining software that extracted only the Markov events in the patient pathway 
defined by the initial model. Rules used to transform clinical events into model states and a 
more detailed description of the whole process are described in Appendix B.   
 
Software was developed to extract patient records from the main PPM dataset using 
database queries and segment these by regimen type and cycle number. A randomly 
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generated integer was used to identify patients for pseudonymisation. Each patient was 
allocated to particular states in the model by applying a data mining process in two main 
stages.  Firstly, events were extracted for each patient from PPM and transformed into a 
single table, ordered by date and time. Creation of the pathway of events for each patient is 
described in detail in Appendix B.  Secondly, this pathway of events was matched to a 
pathway of states in the model described below (Figure 2). A model state reflects a cluster 
of patient events happening within a small time span. In Figure 2, chemotherapy delivery is 
the point at which the pathway starts, repeats and represents state S1 in the model.   
 
Figure 2: The patient pathway model at the beginning of the first iteration.  
S1, patient presents and the chemotherapy goes ahead as normal. S2, patient attends 
hospital for chemotherapy but it is re-scheduled/delayed due to neutropenia. S3, patient is 
admitted acutely to hospital with problems unrelated to their cancer or treatment. S4, 
patient is admitted acutely to hospital with problems related to their cancer or treatment 
(not neutropenic). S5, Patient is admitted acutely to hospital with problems related to their 
cancer or treatment (neutropenic). 
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There were two main steps in each successive data model iteration (Figure 3).  First the 
model was redefined based on the results of data mining from the previous iteration, in 
order to account for complexity revealed by the data that was not previously foreseen; for 
example, a number of patients had blood test results present outside episodes of hospital 
care due to attendances at their GP.  Secondly, there was further refinement of the data 
mining software based on the outcome of the model redefinition. This consisted of the 
addition of validation checks, to ensure that state transitions found in the data did not occur 
between states in the model that did not have a defined path between them.  For example, 
it was initially indicated by the data that patients were still receiving chemotherapy 
treatment after they had died, which created state transitions in the model that were 
clearly invalid. This was caused by the pre-emptive booking of many treatments into the 
system while the patient was still alive which were not subsequently deleted.     
 
The final model schematic of the patient pathway for a cycle of chemotherapy is shown in 
Figure 4. The model includes a number of health states, each with a code. Across both 
regimen and diagnosis combinations, 40,047 health states were analysed (18,529 EC90, 
21,518 OxMdG) which included 69,326 raw events (34,037 EC90, 35,289 OxMdG). S1 is the 
point at which the patient receives chemotherapy; states clustered near the bottom right 
corner represent admissions, whereas those clustered in the bottom left represent events 
when the patient is not admitted, and states clustered in the upper half of Figure 4 
represent events that occur when the patient is due their next cycle of chemotherapy.  
When patients experienced more than one state within a cycle of chemotherapy, they were 
prioritised by the most severe event (Table 1), but counts were kept of the frequency of all 
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health states. An uncomplicated case would be represented by a patient traversing through 
chemotherapy delivery (S1), followed by no contact (D1), then by patient review (R1) and 
back to chemotherapy delivery (S1). By contrast, an emergency admission to hospital and a 
blood test result within 24 hours indicating a neutrophil count of <1.5 x109/L would 
represent state S5 in the model.  Attendance for chemotherapy that was not delivered on 
the expected date and a blood test result within 24 hours indicating a neutrophil count of 
<1.5 x109/L would represent state S2 in the model. 
 
 
Figure 3: The process of creating and iteratively improving the state model. 
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Ethical Considerations 
This work was sanctioned according to local LTHT Research and Development policy. Data 
extraction was carried out under strict information governance procedures, including 
anonymisation of patient-level data.   
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Figure 4: The state model at the end of iteration eight with the description of states.  
S1, patient presents and the chemotherapy goes ahead as normal. D0, home discharge 
following chemotherapy. D1, patient makes no contact with the hospital. D2, telephone 
contact between hospital and patient. D3, patient has an urgent outpatient review. D4, 
patient has an urgent outpatient appointment. D5, death without hospital admission. D7, 
GP attendance with neutropenia. S2, patient attends hospital for chemotherapy but it is re-
scheduled/delayed due to neutropenia. S4, patient is admitted acutely to hospital with no 
evidence of neutropenia. S5, patient is admitted acutely to hospital with evidence of neutropenia. 
S6, patient develops bacteraemia. S8, patient does not develop bacteraemia. S9, patient is 
admitted without neutropenia but develops it during admission. D6, patient dies in hospital. S7, 
patient fully recovers from acute event. F1, patient undergoes further hospital admissions. R1, 
review before the day of planned chemotherapy for patients without hospital admission (in that 
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cycle). R2, review before the day of planned chemotherapy for patients with hospital admission (in 
that cycle). C1, complete all planned chemotherapy. C2, stop planned chemotherapy 
prematurely. C3, re-schedule before hospital attendance to undergo chemotherapy due to 
neutropenia. C4, re-schedule before hospital attendance to undergo chemotherapy due to 
reasons other than neutropenia. C5, patient attends hospital for chemotherapy but it is re-
scheduled  due to reasons other than neutropenia. Neutropenia is defined as a neutrophil 
count of < 1.5 x 109/L. Bacteraemia is defined as any positive blood culture. 
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Results 
Clinical Pathways 
During the first cycle of chemotherapy, 66.4% and 77.4% of patients receiving EC90 and 
OxMdG chemotherapy, respectively, traversed the planned pathway i.e. without 
encountering deviation caused either by treatment toxicity, other health complications or 
personal events unrelated to health such as holidays.  Patients receiving the first cycle of 
EC90 chemotherapy experienced a higher percentage of emergency admission to hospital 
with neutropenia, urgent outpatient review, GP contact with positive test for neutropenia 
and telephone contact between hospital and patient (Table 1).  Conversely, patients 
receiving first cycle of OxMdG chemotherapy experienced a higher percentage of death 
without hospital contact, emergency admissions without neutropenia and day case reviews. 
 
With both regimens, only a small minority of patients received six cycles of chemotherapy 
on the planned pathway (Table 2).  Of the 535 patients with early breast cancer receiving 
the adjuvant EC90, only 27 (5%) completed all six planned cycles of chemotherapy on the 
planned pathway (Table 2). In all, there were 474 pathway variants indicating that almost all 
of the remaining 508 patients followed a unique trajectory through the care system. 
Likewise, of the 420 patients with advanced colorectal cancer receiving palliative OxMdG, 
only 26 (6%) completed six cycles of chemotherapy on the planned pathway and there were 
329 pathway variants. Additionally, the likelihood of an adverse event decreased with each 
successive cycle of EC90 chemotherapy, whereas that likelihood fluctuated with successive 
OxMdG chemotherapy cycles (Table 2).  Over the 6 cycles of chemotherapy, 169 (31.6%) of 
patients receiving EC90 chemotherapy and (190) 45.2% of patients receiving OxMdG 
chemotherapy were admitted to hospital. 
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Table 1: Counts of the main pathways traversed for the first cycle of chemotherapy. 
Ordered from most severe event type to least severe (EC90 in breast cancer patients and 
OxMdG in colorectal cancer patients). *Emergency admissions include those admitted to 
hospital and those who attended the oncology acute assessment unit. Letter/number in 
brackets refers to states in Figure 4. 
 
 
 
  EC90 OxMdG 
Event Count Percentage Cumulative Count Percentage Cumulative 
Death without hospital 
contact (D5) 
0 0.0% 0 14 3.3% 3.3% 
Emergency admission to 
hospital with 
neutropenia (S5) * 
21 3.9% 3.9% 8 1.9% 5.2% 
Emergency admission 
without neutropenia, 
progressing to 
neutropenia whilst in 
hospital (S9) * 
2 0.4% 4.3% 2 0.5% 5.7% 
Emergency admission to 
hospital without 
neutropenia (S4) * 
40 7.5% 11.8% 52 12.4% 18.1% 
Day case review (D4) 3 0.6% 12.3% 9 2.1% 20.2% 
Urgent outpatient review 
(D3) 
19 3.6% 15.9% 0 0.0% 20.2% 
Contacted GP and tested 
positive for neutropenia 
(D7) 
24 4.5% 20.4% 6 1.4% 21.7% 
Telephone contact from 
hospital to patient (D2) 
71 13.3% 33.6% 4 1.0% 22.6% 
No contact (D1)  
355 66.4% 100.0% 325 77.4% 100.0% 
(planned pathway) 
Total 535     420     
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  EC90 OxMdG 
Cycle 
No Contact Admission No Contact  Admission 
(D1) (S5/S4/S9) (D1) (S5/S4/S9) 
1 66.6% 11.8% 77.4% 14.8% 
2 80.0% 6.5% 80.0% 14.2% 
3 72.9% 6.4% 83.0% 8.9% 
4 74.2% 6.9% 81.0% 11.7% 
5 82.7% 5.4% 80.1% 12.1% 
6 86.5% 4.6% 90.0% 5.8% 
All 5.0% 31.6% 6.2% 45.2% 
 
Table 2: Adverse event rate by cycle of chemotherapy (EC90 for breast cancer and OxMdG 
for colorectal cancer). Letter/number in brackets refers to states in Figure 4. No contact 
ƌĞƉƌĞƐĞŶƚƐƚŚĞ “ƉůĂŶŶĞĚƉĂƚŚǁĂǇ ? ? 
 
Discussion 
 
We have demonstrated how data collected as part of routine clinical practice can be used to 
define real-life pathways of care. The key outcomes of this work are the description of the 
reproducible steps followed to successfully construct the pathways, and the clear 
demonstration that clinical pathways of real-life patients are far more complex than those 
defined by standard guidelines, expert opinion, consensus discussions, and clinical trials.   
 
The percentage of patients admitted to hospital over all the six cycles was higher than 
compared to phase III trials (23, 24). This may reflect the real-life, heterogeneous population 
served by the Trust delivering the care. The differences between the pathways of patients 
receiving EC90 and OxMdG chemotherapy may reflect in part the dose intensity and 
myelotoxicity of regimens used in the adjuvant and palliative settings, patient characteristics 
and co-morbidities associated with metastatic cancer.  
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Key strengths of this work are that the data have been collected for routine clinical care 
from a large base population over a period of almost ten years and that the EHR is 
sufficiently mature and detailed (drawing from multiple disparate databases) to enable 
construction of accurate reports of real-life patient pathways. There are, however, 
limitations to using EHR data. The on-going debate in the UK around weekend admissions 
and increased mortality highlights how secondary uses of coded data can be valuable, but 
caution should be applied to avoid misinterpretation by apportioning un-evidenced cause to 
the findings. The detail and accuracy of pathways is limited by the accuracy and detail of 
data recorded.  For example, we did not have electronic records of temperature 
measurements so our transformation rules used the taking of blood cultures as a surrogate 
indicator of fever. There was also inconsistency over time in the chemotherapy regimen 
nomenclature used due to prescribing and recording systems changing, meaning that the 
two regimens studied were only referenced in the system by identical names in a subset of 
the total records. The remaining records were excluded due to uncertainty about whether 
the treatments were identical in drugs used, dosage and method of delivery. In light of the 
recent publication of the Caldicott report (25), which this work pre-dates, we acknowledge 
there was no opt out process for patients from whom data was included in this analysis. This 
was a service evaluation process, with strict information governance procedures, where 
data was extracted, anonymised and analysed by aggregated pathways, not at an individual 
patient level.  
 
Importantly, this pathway mapping provides additional data not apparent from national 
cancer datasets in the UK such as the National Cancer Waiting Times Monitoring Dataset 
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(NCWTMD), Cancer Outcomes and Services Dataset, Systemic Anticancer Therapy Dataset 
and cancer registries (26). Not all care elements are well represented in the national 
datasets such as suspected cancer diagnoses not referred by a general practitioner, care 
prior to a 2-week wait referral and care post referral to community palliative care teams. In 
addition to establishment of and checking adherence to guidelines, mapping real-life 
pathways gives a clear indication of current clinical practice, making it possible to identify 
unmet needs and process delays contributing to delayed targets, such as those mandated by 
the NCWTMD. 
   
Specifically in the context of the research question that prompted this process mining 
initiative, the data has provided a more detailed picture of the issues around the risk of 
developing neutropenic sepsis, including how it is managed in routine practice. We selected 
the populations phenotypically using diagnosis and chemotherapy regimen combinations, 
but this can be narrowed further by selecting populations using parameters such as 
genotype and co-morbidity. We have demonstrated a method of organising clinical data into 
meaningful, quantified pathway models, which practically can be used to identify unmet 
need, model process improvements and inform health economic analyses. Focusing on 
neutropenic sepsis, the models of EC90 and OxMdG, can be used to determine where in the 
pathways home neutrophil monitoring will provide the greatest clinical and economic 
benefits for both patients and care providers.   
 
As EHRs expand across care-provider boundaries, such as the Leeds Care Record, the ability 
to map such integrated pathways provides opportunity to measure health and healthcare in 
ways that have not been possible previously on large numbers of patients, including costs, 
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clinical outcomes and societal impacts.  In the UK NHS payments are based on Healthcare 
Resource Group (HRG) codes, which assume an  “average ? payment for finished consultant 
episodes. The size and frequency of the variance in pathways may therefore adversely affect 
financial performance and the sustainability of an organisation. Basing commissioning 
contracts on idealised planned pathways is, therefore, prone to serious under estimation of 
true costs since many of the variant pathways have very high associated costs, such as 
admissions to intensive care (27). The described pathway in the format of a Markov model, 
is suitable to inform parameter inputs into health economic analysis of the pathways, 
without the need to collect additional data. Also, pathway mapping enables improved 
quality assurance through electronic criteria adherence reporting, computation of quality 
indicators and visualising pathways thus facilitating identification and checking of 
anomalies.   
 
We are applying process mining for real-life pathway modelling to all cancer diagnoses and 
chemotherapy combinations in our large Cancer Centre, in order to model the impact of 
innovative new pathways aiming to reduce the frequency and severity of neutropenic 
complications.  Further detailed knowledge is required to appropriately inform clinical 
practice.  We are addressing this through process mapping at the individual patient level, 
and service line costing to quantify the resource utilisation associated with the departures 
from the planned pathway.  All of this is required to support the investment in research 
applied to addressing the unmet needs, and later to facilitate adoption of new pathways if 
trials show potential interventions to be clinically effective. 
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In conclusion, real life healthcare pathways are highly variable. This paper represents 
 “ƉƌŽŽĨ-of-ƉƌŝŶĐŝƉůĞ ? ƚŚĂƚ, even in the complex field of oncology, comprehensive data 
derived from EHRs can generate clinically important information. Understanding and 
visualising real-life patient-centred pathways should have an important role in identifying 
unmet needs and facilitating quantification of potential and actual impact of proposed 
innovations or changes in practice outside of clinical trials.  There are implications for 
planning and supporting routine care, clinical and operational research, performance 
management and quality improvement.  
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Appendix A 
Explanation of Markov Models 
Markov models can be used to aid health care decision making. They are suited to decisions where 
the timing of events is important and when events may happen more than once, appropriate when 
the strategies being evaluated are of sequential or repetitive nature. They can be used to model the 
cost-effectiveness of interventions by incorporating long terms costs and health outcomes.  Here we 
briefly describe the principles behind Markov models for the uninitiated reader, as there are existing 
comprehensive introductions to Markov modelling (1, 2). 
A cluster of clinical events are simplified by defining them as a clinically important health states or 
Markov states.  For example, in our model, a patient in the health state of febrile neutropenia, had 
an entry in the hospital admissions table, was neutropenic, had blood cultures taken which did not 
grow a pathogenic organism.  Markov models assume that the health states are mutually exclusive 
as a patient cannot be in more than one state at any one time.  The transition of a patient from one 
health state to another is assigned a probability, known as the transition probability.  In our work, 
this probability was defined by the patient data from the electronic health records.  Markov models 
represent repetitive processes over time whereby the patient passes through the same health state 
on more than one occasion, represented in our model by the delivery of chemotherapy.  Patients 
can therefore, only exit the repetitive model via defined exit states, which in our model exist as one 
of only three states; complete chemotherapy, stop chemotherapy prematurely, death.  There is also 
an assumption that transition to future states depend only on the current state, and not on any 
events that occurred before the current state.  This is known as the Markov assumption.  For 
example, in our model, a patient defined as being treated for febrile neutropenia (A3,S5,M1,S8), is 
dependent only on the current health state (blood cultures being taken, which is A3, S5, M1), which 
is in no way influenced by the occurrence of febrile neutropenia in previous chemotherapy cycles.        
Markov models enable estimates of cost and outcomes associated with disease and intervention.  
This is done by assigning estimates of resource usage and health outcomes to health states and 
transitions between states, then running the model over a large number of the repeated Markov 
cycles.  In this way, the cost and effectiveness of a proposed intervention can be modelled using 
assumptions of the effect on transition probabilities.  Drawing the above together, the steps 
commonly followed to construct a Markov model are; deciding on the health/Markov states, 
defining acceptable transitions, identifying transition probabilities, identifying health outcomes, then 
running the model over repeated Markov cycles.   
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 Appendix B 
Detailed description of the development of the datamining software and pathway models. 
In early iterations of the software for this project, the full analysis took around 20 hours to 
run on a machine with an Intel Core I7 processor with 16GB of memory, but it was realised 
that patients could be processed independently of each other and the time to run was 
reduced to around 3 hours by using multithreading. 
The warehousing process is done in three stages: 
Stage 1 
A cryptographically secure random integer for each patient is generated to be used as an 
anonymous identifier. This is stored in a separate database on a secure server within the 
Trust, and the patient is only referenced by their anonymous identifier in the warehouse 
database. 
The relevant data for this study is stored in many different tables in the PPM database, for 
example, admission and discharge event data is stored in the admissions table, and 
chemotherapy administration event data is stored in the chemotherapy table. Events from 
all relevant PPM Tables are merged into one raw events table containing the date and time 
that each event happened, a code to indicate the type of event and code(s) to indicate 
additional attributes of the event that will be used for the state categorisation rules in stage 
2. Merging the events into one table makes it easy for the software to iterate over each 
event in sequence during stage 2. 
A copy of the regimens table from PPM is created, containing data from only the patients 
selected in the study, and with columns removed that are not relevant for this study. 
Computed columns are added that do not exist in PPM; the regimen end date is calculated 
by taking the start date of the last cycle in the regimen and adding the cycle length. The 
diagnosis that the regimen is indicated for is inferred ďǇƚĂŬŝŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐĚŝĂŐŶŽƐŝs that is 
closest to the regimen start date. This table will assist in creating reports with results 
categorised by regimen and or diagnosis 
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A copy of the Cycles table from PPM is created, with only the necessary data, and with 
additional computed column end date calculated by taking the start date of the next cycle if 
there is one, or the start date of the current cycle plus the cycle length. This table will assist 
with categorising results by cycle number. 
Stage 2 
dŚĞĞǀĞŶƚƐŝŶƚŚĞƌĂǁĞǀĞŶƚƐƚĂďůĞĨŽƌŵĂƐŝŶŐůĞĐŽŶĐƵƌƌĞŶƚƉĂƚŚǁĂǇĨŽƌĞĂĐŚƉĂƚŝĞŶƚ ?dŚŝƐ
ƐƚĂŐĞŽĨƚƌĂŶƐĨŽƌŵĂƚŝŽŶĂƚƚĞŵƉƚƐƚŽĨŝƚƚŚŝƐƉĂƚŚǁĂǇƚŽƚŚĞŵŽĚĞů  ?&ŝŐƵƌĞ  ? ŝŶŵĂŶƵƐĐƌŝƉƚ ?
ĚĞĨŝŶĞĚďǇƚŚĞƌĞƐĞĂƌĐŚƚĞĂŵ ?dŚŝƐƐƚĂŐĞƵƐĞƐƚŚĞĨŽůůŽǁŝŶŐƉƌŽĐĞƐƐ P 
 
x &ŽƌĞĂĐŚƉĂƚŝĞŶƚƚŚĞĞǀĞŶƚƐĨƌŽŵƚŚĞƌĂǁĞǀĞŶƚƐƚĂďůĞĂƌĞůŽĂĚĞĚŝŶƚŽŵĞŵŽƌǇ ?ůů
ĞǀĞŶƚƐďĞĨŽƌĞƚŚĞŝƌĨŝƌƐƚĐŚĞŵŽƚŚĞƌĂƉǇĂĚŵŝŶŝƐƚƌĂƚŝŽŶĞǀĞŶƚĂƌĞƐŬŝƉƉĞĚĂƐƚŚŝƐƐƚƵĚǇ
ŝƐŶŽƚĐŽŶĐĞƌŶĞĚǁŝƚŚĞǀĞŶƚƐďĞĨŽƌĞƚŚŝƐ ? 
x ĂĐŚĞǀĞŶƚŝƐŝƚĞƌĂƚĞĚŽǀĞƌĂŶĚƚŚĞƌƵůĞƐŝŶdĂďůĞ ?ĂƌĞƵƐĞĚƚŽĚĞĐŝĚĞƚŚĞ
ĂƉƉƌŽƉƌŝĂƚĞŵŽĚĞůƐƚĂƚĞ ? 
x tŚŝůƐƚƚŚĞƐĞƐƚĂƚĞƐĂƌĞďĞŝŶŐĐŽŵƉƵƚĞĚ ?ƚƌĂŶƐŝƚŝŽŶǀĂůŝĚŝƚǇŝƐĂůƐŽĐŚĞĐŬĞĚ ?
ƚƌĂŶƐŝƚŝŽŶĨƌŽŵŽŶĞŵŽĚĞůƐƚĂƚĞƚŽĂŶŽƚŚĞƌŝƐǀĂůŝĚŝĨƚŚĞƌĞŝƐĂůŝŶĞďĞƚǁĞĞŶƚŚĞŵŽŶ
ƚŚĞŵŽĚĞůĚŝĂŐƌĂŵ ?ĨŽƌĞǆĂŵƉůĞ^ ?ƚŽ ?ǁŽƵůĚďĞǀĂůŝĚ ?ďƵƚ^ ?ƚŽ ?ǁŽƵůĚďĞ
ŝŶǀĂůŝĚ ?ůƚŚŽƵŐŚƐŽŵĞƚƌĂŶƐŝƚŝŽŶƐĂƌĞǀĂůŝĚƚŚĂƚĂƌĞŶŽƚƌĞƉƌĞƐĞŶƚĞĚŝŶ&ŝŐƵƌĞ ? ?ĂƐ
ĨƵƌƚŚĞƌƐŝŵƉůŝĨŝĐĂƚŝŽŶŽĨĐĞƌƚĂŝŶĞǀĞŶƚƐĞƋƵĞŶĐĞƐƚĂŬĞƐƉůĂĐĞůĂƚĞƌŽŶ ?ĚĞƐĐƌŝďĞĚŝŶ
ƐƚĂŐĞ ? ? ?/ĨĂŶŝŶǀĂůŝĚƚƌĂŶƐŝƚŝŽŶŝƐĚĞƚĞĐƚĞĚƚŚĞŶƚŚŝƐŝƐĂĚĚĞĚƚŽĂŶĞƌƌŽƌůŽŐ ?ůů
ŝŶǀĂůŝĚƚƌĂŶƐŝƚŝŽŶƐŵƵƐƚďĞŝŶǀĞƐƚŝŐĂƚĞĚďǇĞǆĂŵŝŶŝŶŐĚĂƚĂƌĞĐŽƌĚƐŝŶWWDŵĂŶƵĂůůǇ ?
dŚĞŵŽƐƚĐŽŵŵŽŶĐĂƵƐĞƐŽĨƚŚĞƐĞǁŝůůďĞŝŶǀĂůŝĚŝŶƉƵƚĚĂƚĂ ?ŝŶĐŽŵƉůĞƚĞŝŶƉƵƚĚĂƚĂ ?
ŽƌĂŶŝŶĐŽŵƉůĞƚĞŵŽĚĞů ? 
 
Stage 3 
dŚĞ ƐĞƋƵĞŶĐĞ ŽĨ ƐƚĂƚĞƐ ŽƵƚƉƵƚ ďǇ ƐƚĂŐĞ  ? ĐĂŶ ĐŽŶƚĂŝŶ ƐĞƋƵĞŶĐĞƐ ŽĨ ĞǀĞŶƚƐ ƚŚĂƚ ĂƌĞ ƚŽŽ
ĐŽŵƉůŝĐĂƚĞĚĨŽƌƚŚĞŵŽĚĞů ŝŶ&ŝŐƵƌĞ  ?ƚŽĞĂƐŝůǇƌĞƉƌĞƐĞŶƚƚŚĞŵ ?&ŽƌĞǆĂŵƉůĞĂƉĂƚŝĞŶƚĐĂŶ
ŚĂǀĞŵĂŶǇĂĚŵŝƐƐŝŽŶƐ ?ƚĞůĞƉŚŽŶĞĨŽƌĂĚǀŝĐĞŵĂŶǇƚŝŵĞƐ ?ŽƌŚĂǀĞĂŶǇĐŽŵďŝŶĂƚŝŽŶŽĨŵĂŶǇ
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ĞǀĞŶƚƐ ?dŚŝƐǁŽƵůĚŵĂŬĞƚŚĞƌĞƐƵůƚĂŶƚŵŽĚĞůĞǆƚƌĞŵĞůǇĐŽŵƉůĞǆƚŽǀŝƐƵĂůŝƐĞŝĨƚŚĞƉĂƚŚǁĂǇ
ǁĞƌĞƚŽĂĐĐŽŵŵŽĚĂƚĞĂůůŽƵƚĐŽŵĞƐ ?^ŽƚŚŝƐƐƚĂŐĞĂƚƚĞŵƉƚƐƚŽƐŝŵƉůŝĨǇƚŚĞŽƵƚƉƵƚ ? 
 
dŚŝƐ ŝƐ ĂĐŚŝĞǀĞĚ ďǇ ƐƉůŝƚƚŝŶŐ ƚŚĞ ůŽŶŐ ĐŽŵƉůĞǆ ƐĞƋƵĞŶĐĞ ŽĨ ĞǀĞŶƚƐ ŝŶƚŽ ƐŵĂůů ƐĞƚƐ ?  ƐŵĂůů
ĞǀĞŶƚƐĞƚŝƐĂƐĞƋƵĞŶĐĞŽĨŽŶĞŽƌŵŽƌĞĞǀĞŶƚƐƚŚĂƚŝƐĐƌĞĂƚĞĚďǇƐƉůŝƚƚŝŶŐƚŚĞƚƌƵĞƐĞƋƵĞŶĐĞ
ŽĨĞǀĞŶƚƐĂƚĞĂĐŚƉŽŝŶƚǁŚĞƌĞƚŚĞƉĂƚŚǁĂǇĚĞǀŝĂƚĞƐĨƌŽŵƚŚĞŵŽĚĞůŝŶ&ŝŐƵƌĞ ? ?
dŚŝƐ ƉƌŽĐĞƐƐ ŝƐ ƐŚŽǁŶ ǀŝƐƵĂůůǇ ŝŶ &ŝŐƵƌĞ  ? ? dŚĞ ƌĞĚ ƉĂƚŚǁĂǇ ŚŝŐŚůŝŐŚƚƐ ƚŚĞ ƚƌƵĞ ƉĂƚŚǁĂǇ
ƚĂŬĞŶďǇƚŚĞƉĂƚŝĞŶƚƚŚƌŽƵŐŚƚŚĞĨŽůůŽǁŝŶŐƐƚĂƚĞƐ P ^?AN ?AN ?AN^ ?AN^ ?AN^ ? ?dŚŝƐƉĂƚŚǁĂǇ
ŝƐƐƉůŝƚĂƚƚŚĞďůƵĞy ?ƐŝŶƚŽƚŚƌĞĞƐŵĂůůĞǀĞŶƚƐĞƚƐ P 
1. ^ ?AN ? 
2.  ? 
3. ^ ?AN^ ?AN^ ? 
 
dŚĞ ƐĞƚƐ ĂƌĞ ƚŚĞŶ ǁĞŝŐŚƚĞĚ ďǇ ƐĞǀĞƌŝƚǇ ? ĂĐŚ ƐƚĂƚĞ ŝŶ ƚŚĞ ŵŽĚĞů ŚĂƐ Ă ƐĞǀĞƌŝƚǇ ǁĞŝŐŚƚŝŶŐ
 ?ƐŚŽǁŶŝŶdĂďůĞ ?ĂŶĚĐŚŽƐĞŶďĂƐĞĚŽŶŝŵƉĂĐƚƚŽƋƵĂůŝƚǇ-ĂĚũƵƐƚĞĚůŝĨĞǇĞĂƌ ?Y>z ?ĨŽƌƚŚĞ
ƉĂƚŝĞŶƚĂŶĚĐŽƐƚĨŽƌƚŚĞŚŽƐƉŝƚĂů ? ?dŽĐĂůĐƵůĂƚĞƚŚĞƐĞǀĞƌŝƚǇǁĞŝŐŚƚŝŶŐĨŽƌĂƐĞƚ ?ƚŚĞǁĞŝŐŚƚŝŶŐ
ŽĨ Ăůů ŝƚƐ ĐŽŶƐƚŝƚƵĞŶƚ ƐƚĂƚĞƐ ĂƌĞ ƐƵŵŵĞĚ ? ŐŝǀŝŶŐ ƚŚĞĨŽůůŽǁŝŶŐ ǁĞŝŐŚƚŝŶŐƐ ĨŽƌ ƚŚĞ ĂďŽǀĞ
ĞǆĂŵƉůĞ P 
1.  ?A? ?A? ? 
2.  ? 
3.  ?A? ?A? ?A? ? 
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ZĂǁĞǀĞŶƚ ZƵůĞƐ DŽĚĞůƐƚĂƚĞ 
ŚĞŵŽƚŚĞƌĂƉǇ
ĂĚŵŝŶŝƐƚĞƌĞĚ 
ŚĞŵŽƚŚĞƌĂƉǇǁĂƐĚĞůŝǀĞƌĞĚŽŶƚŝŵĞŽƌƵƉƚŽ ?ĚĂǇƐůĂƚĞ ? ^ ? 
ŚĞŵŽƚŚĞƌĂƉǇ ǁĂƐ ANA?  ? ĚĂǇƐ ĚĞůĂǇĞĚ ĂŶĚ ďůŽŽĚ ƚĞƐƚ ƌĞƐƵůƚ
ŝŶĚŝĐĂƚŝŶŐ ŶĞƵƚƌŽƉĞŶŝĂ ĞǆŝƐƚƐ ŝŶ ƚŚĞ ƉĞƌŝŽĚ ŽĨ - ? ƚŽ A? ? ĚĂǇƐ ĨƌŽŵ
ƚŚŝƐĞǀĞŶƚ ? 
 ? 
ŚĞŵŽƚŚĞƌĂƉǇ ǁĂƐ ANA? ? ĚĂǇƐ ĚĞůĂǇĞĚ ĂŶĚ ŶŽ ƌĞƐƵůƚ ŝŶĚŝĐĂƚŝŶŐ
ŶĞƵƚƌŽƉĞŶŝĂ ? 
 ? 
ŵĞƌŐĞŶĐǇĂĚŵŝƐƐŝŽŶ 
EŽ ƌĞƐƵůƚ ŝŶĚŝĐĂƚŝŶŐ ŶĞƵƚƌŽƉĞŶŝĂ ĚƵƌŝŶŐ ĂĚŵŝƐƐŝŽŶ  ?ďĞƚǁĞĞŶ
ĂĚŵŝƐƐŝŽŶĞǀĞŶƚĂŶĚĚŝƐĐŚĂƌŐĞĞǀĞŶƚ ? ? 
^ ? 
 
EĞƵƚƌŽƉĞŶŝĐƌĞƐƵůƚƵƉƚŽ ? ?ŚŽƵƌƐĂĨƚĞƌĂĚŵŝƐƐŝŽŶ ? ^ ? 
EŽŶĞƵƚƌŽƉĞŶŝĐƌĞƐƵůƚĚƵƌŝŶŐƚŚĞ ? ?ŚŽƵƌƐĨŽůůŽǁŝŶŐƚŚĞĂĚŵŝƐƐŝŽŶ
ďƵƚŶĞƵƚƌŽƉĞŶŝĐƌĞƐƵůƚďĞĨŽƌĞĚŝƐĐŚĂƌŐĞ ? 
^ ? 
ĂĐƚĞƌĂĞŵŝĐďůŽŽĚĐƵůƚƵƌĞƌĞƐƵůƚĚƵƌŝŶŐĂĚŵŝƐƐŝŽŶ ^ ? 
EŽĂĐƚĞƌĂĞŵŝĐďůŽŽĚĐƵůƚƵƌĞƌĞƐƵůƚĚƵƌŝŶŐĂĚŵŝƐƐŝŽŶ ^ ? 
ĞĂƚŚĚƵƌŝŶŐĂĚŵŝƐƐŝŽŶ  ? 
ŝƐĐŚĂƌŐĞĂĨƚĞƌ
ĞŵĞƌŐĞŶĐǇĂĚŵŝƐƐŝŽŶ EŽŶĞ 
^ ? 
ůŽŽĚĐŽƵŶƚƌĞƐƵůƚ /ĨƌĞƐƵůƚŝŶĚŝĐĂƚĞƐŶĞƵƚƌŽƉĞŶŝĂĂŶĚĚĂƚĞǁĂƐŽƵƚƐŝĚĞŽĨĂĚŵŝƐƐŝŽŶ  ? 
dĞůĞƉŚŽŶĞĐŽŶƚĂĐƚ EŽŶĞ  ? 
hƌŐĞŶƚŽƵƚƉĂƚŝĞŶƚ
ƌĞǀŝĞǁ EŽŶĞ 
 ? 
ĞĂƚŚ /ĨĚĂƚĞǁĂƐŽƵƚƐŝĚĞŽĨĂĚŵŝƐƐŝŽŶ  ? /ĨĚƵƌŝŶŐĂĚŵŝƐƐŝŽŶ  ? 
EŽŶ-ĞŵĞƌŐĞŶĐǇ
ĂĚŵŝƐƐŝŽŶ 
/Ĩ ĐŚĞŵŽƚŚĞƌĂƉǇ ǁĂƐ ƐĐŚĞĚƵůĞĚ ƚŽ ďĞ ĚĞůŝǀĞƌĞĚ ĚƵƌŝŶŐ ƚŚŝƐ
ĂĚŵŝƐƐŝŽŶ ? ?ďƵƚǁĂƐŶ ?ƚ ?ĂŶĚŶĞƵƚƌŽƉĞŶŝĐďůŽŽĚĐŽƵŶƚƌĞƐƵůƚĞǆŝƐƚƐ
AMA? ?ĚĂǇƐĨƌŽŵĂĚŵŝƐƐŝŽŶ 
^ ? 
/Ĩ ĐŚĞŵŽƚŚĞƌĂƉǇ ǁĂƐ ƐĐŚĞĚƵůĞĚ ƚŽ ďĞ ĚĞůŝǀĞƌĞĚ ĚƵƌŝŶŐ ƚŚŝƐ
ĂĚŵŝƐƐŝŽŶ ? ?ďƵƚǁĂƐŶ ?ƚ ?ĂŶĚŶŽĞǀŝĚĞŶĐĞŽĨŶĞƵƚƌŽƉĞŶŝĂ 
 ? 
EŽĐŚĞŵŽƚŚĞƌĂƉǇƐĐŚĞĚƵůĞĚ ?ĚƵƌŝŶŐƚŚŝƐĂĚŵŝƐƐŝŽŶĂŶĚůĞŶŐƚŚŽĨ
ƐƚĂǇAMA? ?ĚĂǇ 
 ? 
 ?ĂůĐƵůĂƚĞĚďǇƚĂŬŝŶŐƉƌĞǀŝŽƵƐĐǇĐůĞĚĂƚĞƉůƵƐĐǇĐůĞůĞŶŐƚŚ 
Table B1: The rules used in stage 2 to transform raw events into model states. 
 
 
/Ŷ ƚŚŝƐ ƐƚƵĚǇ ƚŚĞ ƌĞƐĞĂƌĐŚĞƌƐ ǁĞƌĞ ƉƌŝŵĂƌŝůǇ ŝŶƚĞƌĞƐƚĞĚ ŝŶ  ?ĨŽƌ ĞĂĐŚ ƉĂƚŝĞŶƚ ?  ?ŝ ? ƚŚĞ ŵŽƐƚ
ƐĞǀĞƌĞƐŵĂůůĞǀĞŶƚƐĞƚ ?ĂŶĚ ?ŝŝ ?ƚŚĞĨƌĞƋƵĞŶĐǇŽĨŽĐĐƵƌƌĞŶĐĞŽĨĞĂĐŚŵŽĚĞůƐƚĂƚĞ ?ƌĞŐĂƌĚůĞƐƐ
ŽĨ ŝŶĐůƵƐŝŽŶŝŶƐŵĂůůĞǀĞŶƚƐĞƚƐ ? dŽƐĞƌǀĞƚŚĞƐĞƚǁŽŝŶƚĞƌĞƐƚƐ ?ĞĂĐŚƐƚĂƚĞŝŶƚŚĞŵŽĚĞůǁĂƐ
ŐŝǀĞŶƚǁŽŶƵŵďĞƌƐŽƌĐŽƵŶƚƐƚŽďĞŽƵƚƉƵƚŝŶƚŚĞĂŐŐƌĞŐĂƚĞƌĞƉŽƌƚĚĂƚĂ ?dŚĞĨŝƌƐƚĐŽƵŶƚǁĂƐ
ƚŚĞƐĞǀĞƌŝƚǇĐŽƵŶƚ ?ǁŚŝĐŚŝŶĚŝĐĂƚĞĚŚŽǁŵĂŶǇƉĂƚŝĞŶƚƐĞǆƉĞƌŝĞŶĐĞĚƚŚĞƐƚĂƚĞĂƐƉĂƌƚŽĨƚŚĞŝƌ
ŵŽƐƚ ƐĞǀĞƌĞ ƐŵĂůů ĞǀĞŶƚ ƐĞƚ ? dŚĞ ƐĞĐŽŶĚ ĐŽƵŶƚ ǁĂƐ ƚŚĞ ĨƌĞƋƵĞŶĐǇ ĐŽƵŶƚ ? ǁŚŝĐŚ ŝŶĚŝĐĂƚĞĚ
ŚŽǁŵĂŶǇƚŝŵĞƐĞĂĐŚƐƚĂƚĞŚĂĚŽĐĐƵƌƌĞĚŝŶƚŽƚĂů ?dŚĞƐĞǀĞƌŝƚǇĐŽƵŶƚƚŚĞŶŚĂƐƚŚĞƉƌŽƉĞƌƚǇ
ƚŚĂƚ ŝĨĂƐŝŶŐůĞƉĂƚŚǁĂǇƐƉůŝƚƐ ŝŶƚŽŵĂŶǇƚŚĞŶƚŚĞƐĞǀĞƌŝƚǇĐŽƵŶƚďĞĨŽƌĞƚŚĞƐƉůŝƚǁŝůůĞƋƵĂů
ƚŚĞ ƐƵŵ ŽĨ ƚŚĞ ƐĞǀĞƌŝƚǇ ĐŽƵŶƚ ŽŶ ĞĂĐŚ ŽĨ ŝƚƐ ďƌĂŶĐŚĞƐ ? ǁŚŝĐŚ ŝƐ ƵƐĞĨƵů ĨŽƌ ĐŚĞĐŬŝŶŐ ĚĂƚĂ
ǀĂůŝĚŝƚǇĂŶĚĨŽƌŵĂŬŝŶŐŝŶĨĞƌĞŶĐĞƐďĂƐĞĚŽŶĚŝƐƚŝŶĐƚƐĞƚƐŽĨƉĂƚŝĞŶƚƐ ?dŚĞĨƌĞƋƵĞŶĐǇĐŽƵŶƚŝƐ
ƵƐĞĨƵůĨŽƌĞƐƚŝŵĂƚŝŶŐƚŽƚĂůĐŽƐƚďǇƐŝŵƉůǇŵƵůƚŝƉůǇŝŶŐƚŚĞĨƌĞƋƵĞŶĐǇĐŽƵŶƚŽĨĂƐƚĂƚĞďǇƚŚĞ
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ĐŽƐƚƉĞƌŽĐĐƵƌƌĞŶĐĞŽĨĂƐƚĂƚĞ ?ZĞƉŽƌƚƐǁĞƌĞƚŚĞŶŐĞŶĞƌĂƚĞĚƐŚŽǁŝŶŐƚŚĞƐĞǀĞƌŝƚǇĐŽƵŶƚĂŶĚ
ĨƌĞƋƵĞŶĐǇĐŽƵŶƚĨŽƌĞǀĞƌǇƐƚĂƚĞŝŶƚŚĞŵŽĚĞů ?ĂŶĚĐŽƵůĚďĞŐƌŽƵƉĞĚďǇĂŶǇĐŽŵďŝŶĂƚŝŽŶŽĨ
ƌĞŐŝŵĞŶ ?ŝŶĚŝĐĂƚŝŽŶĂŶĚĐǇĐůĞŶƵŵďĞƌ ? 
 
 
 
Figure B1: An excerpt of the model in Figure 4 used to demonstrate the process of splitting a 
long series of events into small event sets. 
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State Weighting Description 
S1 0 Chemotherapy received 
D0 0 Home discharge 
D1 0 No contact 
D7 1 GP contact with neutropenia 
D2 2 Telephone for advice 
D3 3 Urgent OP review 
D4 4 Day case review 
S4 5 Non-neutropenic emergency admission 
S9 6 Non-neutropenic emergency admission progressing to neutropenia during stay  
S5 7 Neutropenic emergency admission 
S6 0 No bacteraemia during admission 
S8 1 Bacteraemia during admission 
S7 0 Discharged from hospital 
D6 4 Death during hospital stay 
D5 9 Death outside of hospital stay 
C4 1 Reschedule before hospital attendance due to other reasons 
C3 2 Reschedule before hospital attendance due to neutropenia 
C5 3 Hospital attendance but no chemotherapy due to other reasons 
S2 4 Hospital attendance but no chemo due to neutropenia 
C2 5 Stop chemotherapy before completing the regimen 
C1 5 Complete all planned chemotherapy 
Table B2: The severity weighting of all major states in the model. 
 
 
